Svenska
Glossary
Search
Latest News
Upcoming Events
Februari 8, 2010
NeuroNovas läkemedelskandidat sNN0029 för ALS får särläkemedelsstatus av europeiska läkemedelsmyndigheten
February 8, 2010
NeuroNova´s drug candidate sNN0029 for ALS/Lou Gehrig´s disease receives orphan designation by the European Medicines Agency (EMEA)
May 3-6, 2010. BIO International Convention, McCormick Place, Chicago, IL, USA.
© NeuroNova AB, Sweden, Tel: +46 (0)8 786 0900, Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Sitemap
Site policy
Site last updated: Monday 8 February 2010
Project Pipeline
Project
Indication
Pre-clin.
IND
Phase I/II
Phase II
Phase III
sNN0029
ALS
sNN0031
Parkinson's disease
More about our Projects
Business Development
NeuroNova’s business strategy centers on developing novel therapeutic products based on neurogenesis in areas of high unmet medical need in neurodegenerative diseases.
More about business development.
